Living With Mesothelioma-My diary- Message from Mesothelioma Uk and A Survey for Mesothelioma Patients and Carers to complete Please

Woke up very early so laid there and then got up for 5am Louis came and laid at my feet but then decided it was to earlyand went back to bed but when Im up Im up. grrr!!

I pottered around until Ray got up and then we had breakfast together.

Usual housework was done as Ray took Louis out for his walk.















Ray had to go for his last needle appointment so we went with him and I walked Louis around again –that dog has us on a string









We got cold so came back and waited in the car.

There is a survey from British Lung Foundation if you would like to fill up. It is to find out how informed we are on diagnosis.

The British Lung Foundation, in partnership with the Mick Knighton Mesothelioma Research Fund, would like to try and get a better picture of people’s experiences of living with mesothelioma. We are asking you to fill out the enclosed survey, which covers diagnosis, asbestos exposure and the legal process, as well as some general questions. All responses will be treated as anonymous.

Also When I got home I had a email from Mesothelioma Uk and a Newsletter that was of interest

An article written by Dr Jeremy Steele at Barts, London.
Published in the latest Mesothelioma UK newsletter, Spring 2013.

Nonselective Transarterial Chemoperfusion: A Palliative Treatment for
Pleural Mesothelioma. By T Vogl, S Lindemayr, N Naguib, J Gurung, N
Nour-Eldin, S Zangos, E Mbalisike. Goethe University, Frankfurt, Germany

Over several years Professor Thomas Vogl and his team
in Frankfurt have been treating patients with pleural mesothelioma with a technique called ‘Nonselective Transarterial Chemoperfusion’. This is a new way of
delivering cytotoxic chemotherapy to patients with pleural mesothelioma. It is an extension of similar techniques used
in the treatment of cancers in other parts of the body, notably the liver.
Techniques similar to that described in this article are in use in the NHS in the UK, but not for patients with
mesothelioma. Professor Vogl’s technique has been the subject of interest in the UK, especially from patients with mesothelioma who, understandably, want to hear about
all possible treatments. Doctors and nurses caring for people with mesothelioma have also been interested to hear more about this treatment. British doctors have had to be cautious about recommending treatment with nonselectivetransarterial chemoperfusion to patients because no full results for patients with mesothelioma have been available until now.
Professor Vogl’s team have now presented results on 39 patients treated with transarterial chemoperfusion.
The median survival time from first
treatment was 17 months, with a mean
progression-free survival time of 2.6
months (i.e. 79 days). Progression-
free survival is a key measure in a trial
of this type as it is sometimes used
to determine the likely benefit of a
By comparison, the progression-free survival in the clinical trial of Pemetrexed and Cisplatin for previously untreated
patients (published in the Journal of
Clinical Oncology by Vogelzang, 2003)
was 5.7 months. An even closer comparison is with
patients treated with Pemetrexed and Cisplatin as second-line chemotherapy (as in Vogl’s trial). According to the
results, these patients had a median survival time of 15.3 months (Manegold,
Annals of Oncology, 2005). And in the randomised ‘MARS’ trial conducted in the UK, the median survival for patients not treated with radical surgery (i.e. with intravenous chemotherapy only)
was 19.5 months (Treasure, Lancet Oncology, 2011).
Professor Vogl and team say the following about transarterial chemoperfusion: ‘This procedure could be of benefit in the treatment of this tumour in stages when it is
unresectable’ and, ‘that our study results will open up the horizon for more studies to be performed.’ Professor Vogl concludes that transarterial chemoperfusion may have the potential to yield positive results and response
in the treatment of recurrent and/or unresectable pleural mesothelioma.
What needs to be done is a randomised trial of transarterial chemoperfusion versus intravenous chemotherapy.
Only a randomised trial can show if transarterial chemoperfusion offers any benefits to patients above and beyond what we can already do. The results presented in the recent article cannot confirm or deny such a benefit.

Consultant Medical Oncologist Barts and the London NHS Trust
Nonselective Transarterial Chemoperfusion: A Palliative Treatment for
Pleural Mesothelioma. By T Vogl, S Lindemayr, N Naguib, J Gurung, N
Nour-Eldin, S Zangos, E Mbalisike. Goethe University, Frankfurt, Germany


Rays Blog

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s